User profiles for Afsaneh Alavi
afsaneh alaviMayo Clinic Verified email at mayo.edu Cited by 8069 |
Diabetic foot ulcers: Part I. Pathophysiology and prevention
A Alavi, RG Sibbald, D Mayer, L Goodman… - Journal of the American …, 2014 - Elsevier
Diabetes mellitus is a serious, life-long condition that is the sixth leading cause of death in
North America. Dermatologists frequently encounter patients with diabetes mellitus. Up to 25…
North America. Dermatologists frequently encounter patients with diabetes mellitus. Up to 25…
Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment
A Alavi, LE French, MD Davis, A Brassard… - American journal of …, 2017 - Springer
Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical
clinical presentations. Its pathophysiology is complex and not fully explained. Recent …
clinical presentations. Its pathophysiology is complex and not fully explained. Recent …
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa …
Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with
profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and …
profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and …
Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study
A Alavi, N Anooshirvani, WB Kim, P Coutts… - American journal of …, 2015 - Springer
Background Hidradenitis suppurativa (HS) is a chronic relapsing condition with a clinical
picture that includes solitary nodules; diffuse, painful abscesses; malodorous drainage; sinus …
picture that includes solitary nodules; diffuse, painful abscesses; malodorous drainage; sinus …
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised …
Background Few therapeutic options are available for patients with moderate-to-severe
hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with …
hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with …
Radiodermatitis: a review of our current understanding
Radiodermatitis (radiation dermatitis, radiation-induced skin reactions, or radiation injury) is
a significant side effect of ionizing radiation delivered to the skin during cancer treatment as …
a significant side effect of ionizing radiation delivered to the skin during cancer treatment as …
What's new: Management of venous leg ulcers: Treating venous leg ulcers
A Alavi, RG Sibbald, TJ Phillips, OF Miller… - Journal of the American …, 2016 - Elsevier
Venous leg ulcers account for approximately 70% of all leg ulcers and affect 2.2 million
Americans annually. After a comprehensive patient and wound assessment, compression …
Americans annually. After a comprehensive patient and wound assessment, compression …
Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options
…, B Ladizinski, K Lee, A Baibergenova, A Alavi - Journal of the American …, 2013 - Elsevier
Necrobiosis lipoidica (NL) is a rare chronic granulomatous disease that has historically been
associated with diabetes mellitus. Debate exists regarding the etiology and pathogenesis …
associated with diabetes mellitus. Debate exists regarding the etiology and pathogenesis …
Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis
… Gary Sibbald MD e , Afsaneh Alavi MD, MSc e … Disclosure: Dr Alavi is an advisor, consultant,
and speaker for AbbVie and Janssen. She is an investigator for AbbVie and Novartis and …
and speaker for AbbVie and Janssen. She is an investigator for AbbVie and Novartis and …
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project
Background A needs assessment for patients with hidradenitis suppurativa (HS) will support
advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. …
advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. …